X Zhu,
F Nishimura,
K Sasaki,
M Fujita,
JE Dusak,
J Eguchi,
W Fellows-Mayle,
WJ Storkus,
PR Walker,
AM Salazar,
H Okada.
(2007)
" Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
"
J Transl Med
5.
10
PMID:
17295916
DOI:
10.1186/1479-5876-5-10
|
Abstract and Keywords
S Szmania,
S Gnjatic,
G Tricot,
K Stone,
F Zhan,
A Moreno,
B Thuro,
J Melenhorst,
J Barrett,
J Shaughnessy,
LJ Old,
B Barlogie,
VG Brichard,
F van Rhee.
(2007)
" Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
"
J Immunother
30.
847-54
PMID:
18049337
DOI:
10.1097/CJI.0b013e318158fcff
|
Abstract and Keywords
JM Bustamante,
LM Bixby,
RL Tarleton.
(2008)
" Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.
"
Nat Med
14.
542-50
PMID:
18425131
DOI:
10.1038/nm1744
|
Abstract and Keywords
KB Walsh,
D Marsolais,
MJ Welch,
H Rosen,
MB Oldstone.
(2010)
" Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.
"
Virology
397.
260-9
PMID:
19962171
DOI:
10.1016/j.virol.2009.08.043
|
Abstract and Keywords
S Lee,
H Yagita,
TJ Sayers,
E Celis.
(2010)
" Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
"
Cancer Immunol Immunother
59.
1073-81
PMID:
20213120
DOI:
10.1007/s00262-010-0834-0
|
Abstract and Keywords
LM Wood,
ZK Pan,
V Shahabi,
Y Paterson.
(2010)
" Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.
"
Cancer Immunol Immunother
59.
1049-58
PMID:
20213121
DOI:
10.1007/s00262-010-0830-4
|
Abstract and Keywords
OE Rahma,
E Ashtar,
M Czystowska,
ME Szajnik,
E Wieckowski,
S Bernstein,
VE Herrin,
MA Shams,
SM Steinberg,
M Merino,
W Gooding,
C Visus,
AB Deleo,
JK Wolf,
JG Bell,
JA Berzofsky,
TL Whiteside,
SN Khleif.
(2011)
" A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
"
Cancer Immunol Immunother
61.
373-84
PMID:
21927947
DOI:
10.1007/s00262-011-1100-9
|
Abstract and Keywords